Ophthalmic cancer, commonly referred as eye cancer, is a malignancy that grows in the eye. Malignant cells are cancerous cells that grow uncontrollably at a rapid pace. They also spread to others tissues of the body. Ocular melanoma is type of cancer that develops in cells which produces pigment that give color to the eyes. Ocular melanoma develops in uvea called choroid which is a pigment layer lining the eyeball. Most melanomas develop in the choroid; however, they can also develop in the iris (colored area around pupil). Melanomas in iris grow slowly and do not spread to other parts of the body. Primary intraocular lymphoma, is a type of cancer which involves lymphocytes. This is a rare type of cancer, which usually occurs in individuals with weak immune systems. The third type of cancer is retinoblastoma, which is a caused due to genetic mutation in retina, a light sensitive tissue, where retinal nerve cells begin to grow and multiply and then further spread to other parts of eyes.
The ophthalmic cancer treatment market is driven by increasing prevalence of eye cancer. Rise in the number of eye cancer cases is due to factors such as increase exposure to UV radiation from laptops, mobile phones, and greenhouse effect. Immunological disorders weaken immune system. People with weak immune systems are at a higher risk of developing eye cancer. Furthermore, government initiatives to improve health care facilities by providing treatment at minimal cost has boosted the ophthalmic cancer treatment market. However, lack of awareness regarding the early symptoms of eye cancer lead to delayed detection & onset of treatment and also cost incurred for the treatment for the underprivileged and underdeveloped parts of the world restrain the ophthalmic cancer treatment market.
The global ophthalmic cancer treatment market has been segmented based on route of administration, class of drug, end-user, and geography. In terms of route of administration, the global ophthalmic cancer treatment market has been divided into topical administration, intraocular administration, intrathecal administration, and systemic administration. Based on class of drugs, the market has been segregated into anti-metabolites, alkylating agents, antineoplastics, and monoclonal antibodies. In terms of end-user, the global ophthalmic cancer drugs market has been categorized into hospitals, ambulatory surgical centers, and cancer research institutes.
Based on regions, the global ophthalmic cancer treatment market has classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The ophthalmic cancer affects equally to men and women globally. In the U.S., melanoma is the most common type of cancer, followed by lymphoma. In Europe as well, incidence of ocular myeloma is high. Caucasians are more susceptible to melanoma than Africans. In the U.S. as well as Europe, ocular melanoma affects people above the age of 55 years. Therefore, the ophthalmic cancer treatment market is expected to expand in the U.S. and Europe. Choroidal melanoma is most common in adults in Asia Pacific. It affects equally to all with increasing age, mostly above 60 years of age, irrespective of gender. Even in Asia Pacific, the incidence is higher in the fairly pigmented group
The major players operating in the ophthalmic cancer treatment market are Merck & Co. Inc., F. Hoffmann La-Roche Ltd., Novartis AG., Johnson & Johnson, GlaxoSmithKline, Genetech Inc. and others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.